Memphasys Limited (MEM.AX)

AUD 0.01

(0.0%)

Market Cap (In AUD)

10.57 Million

Revenue (In AUD)

60 Thousand

Net Income (In AUD)

-4.44 Million

Avg. Volume

963.44 Thousand

Currency
AUD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
0.004-0.014
PE
-
EPS
-
Beta Value
0.968
ISIN
AU000000MEM5
CUSIP
Q59718108
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. David Ali
Employee Count
-
Website
https://www.memphasys.com
Ipo Date
2007-05-11
Details
Memphasys Limited develops, manufactures, and sells cell and protein separation devices, and related consumables for the healthcare, veterinary, and biotechnology market sectors in Australia. It primarily develops Felix, a novel automated device for quickly and gently separating high quality sperm from a raw semen sample for use in human IVF procedures. In addition, the company's product pipeline include ROSA, a rapid oxidative stress assay; Samson Device, rapid equine pregnancy prediction assay; SemPort, a central lab human semen analysis from distantly located donors; and AI-Port. An ambient temperature semen transport device used for animal artificial insemination. Memphasys Limited was formerly known as NuSep Holdings Limited and changed its name to Memphasys Limited in July 2016. The company was incorporated in 2006 and is based in Homebush, Australia.